碧桂園(02007.HK):賣出看漲期權協定價每份將調整為14.53港元
格隆匯6月6日丨碧桂園(02007.HK)公佈,因派付末期股息,(i)第一債券即於2023年到期的78.3億港元4.50%有抵押擔保可換股債券的換股價將由每股股份10.47港元調整為10.21港元;(ii)賣出看漲期權的協定價將由每份賣出看漲期權14.89港元調整為14.53港元;及(iii)買入看漲期權的協定價將由每份買入看漲期權10.47港元調整為10.21港元,以上所有調整均自2022年6月7日起生效。
此外,因派付末期股息,第二債券即於2026年到期的39億港元4.95%有抵押擔保可換股債券的換股價將由每股股份8.10港元調整為7.92港元,自2022年6月13日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.